[PDF][PDF] Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors

J Choi, SY Lee - Immune network, 2020 - synapse.koreamed.org
Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy

J Wei, J Mu, Y Tang, D Qin, J Duan, A Wu - Journal of nanobiotechnology, 2023 - Springer
Ophthalmic inflammatory diseases, including conjunctivitis, keratitis, uveitis, scleritis, and
related conditions, pose considerable challenges to effective management and treatment …

Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination

I Papasavvas, CP Herbort - Journal of Ophthalmic Inflammation and …, 2021 - Springer
Abstract Background/purpose Vogt-Koyanagi-Harada (VKH) disease is a primary stromal
choroiditis with bilateral granulomatous panuveitis. If initial-onset VKH is treated early and …

Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of …

S Gandhi, MR Pandey, K Attwood, W Ji… - Clinical Cancer …, 2021 - AACR
Purpose: Increased β-adrenergic receptor (β-AR) signaling has been shown to promote the
creation of an immunosuppressive tumor microenvironment (TME). Preclinical studies have …

Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt–Koyanagi–Harada disease: an updated review

CP Herbort Jr, I Tugal-Tutkun, A Abu-El-Asrar, A Gupta… - Eye, 2022 - nature.com
Abstract Vogt–Koyanagi–Harada (VKH) disease is a primary autoimmune stromal
choroiditis. This review aimed to provide a novel perspective of the disease. We took into …

Eyebrow and eyelash alopecia: A clinical review

B Nguyen, JK Hu, A Tosti - American journal of clinical dermatology, 2023 - Springer
Madarosis is characterized by either complete or partial loss of eyebrow or eyelash hair.
Etiologies for madarosis are varied, and accurate diagnosis is the first step in clinical …

Ocular inflammation induced by immune checkpoint inhibitors

F Chaudot, P Sève, A Rousseau, ATJ Maria… - Journal of Clinical …, 2022 - mdpi.com
Ocular immunotherapy-related adverse events (IRAEs), although rare, can be sight-
threatening. Our objective was to analyze ocular IRAEs diagnosed in France from the …

Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition

MM Sun, RD Levinson, A Filipowicz… - Ocular Immunology …, 2020 - Taylor & Francis
Purpose: To investigate the link between treatment with CTLA-4 and PD-1 checkpoint
blockade inhibitors and the development of noninfectious uveitis. Methods: A survey was …

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief …

CA Urzua, CP Herbort Jr, M Takeuchi… - Journal of Ophthalmic …, 2022 - Springer
Abstract Background Appraisals of Vogt-Koyanagi-Harada disease (VKH) have become
progressively more complete, since its first description in 1906. The availability of new …

Ocular inflammation post-vaccination

Y Zou, K Kamoi, Y Zong, J Zhang, M Yang… - Vaccines, 2023 - mdpi.com
The association between vaccines and ocular disorders has attracted significant attention in
scientific research. Numerous mainstream vaccines are associated with a range of uveitis …